TY - JOUR
T1 - Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma
AU - Schlette, Ellen J.
AU - Medeiros, L. Jeffrey
AU - Goy, Andre
AU - Lai, Raymond
AU - Rassidakis, George Z.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2004
Y1 - 2004
N2 - Purpose: Survivin, a member of the inhibitor of apoptosis (IAP) family, is not detected in normal adult tissues but is overexpressed in various cancers, including some types of lymphoma. The frequency and prognostic significance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown. Materials and Methods: We assessed for survivin expression in 62 ALCL tumors (30 anaplastic lymphoma kinase [ALK]-positive and 32 ALK-negative) obtained before doxorubicin-based chemotherapy. Given that survivin is a target of the STAT3 signaling pathway and STAT3 is activated in ALCL, survivin expression was also correlated with STATS activation. Results: Survivin was expressed in 34 tumors (55%) and did not correlate with ALK. A significant association between survivin expression and STATS activation was observed (P = .007, Fisher's exact test). For the ALK-positive group, the 5-year failure-free survival (FFS) was 34% for patients with survivin-positive ALCL compared with 100% for patients with survivin-negative ALCL (P = .009, log-rank test). For the ALK-negative group, the 5-year FFS was 46% for patients with survivin-positive tumors compared with 89% for patients with survivin-negative tumors (P = .03, log-rank test). Overall survival was similarly worse for patients with survivin-positive tumors in both the ALK-positive and ALK-negative groups. Furthermore, multivariate analysis confirmed the independent prognostic value of survivin expression, along with age older than 60 years and Ann Arbor stage III or IV. Conclusion: Survivin is expressed in approximately half of ALCL tumors and independently predicts unfavorable clinical outcome. Modulation of survivin expression or function may provide a novel target for experimental therapy in patients with ALCL.
AB - Purpose: Survivin, a member of the inhibitor of apoptosis (IAP) family, is not detected in normal adult tissues but is overexpressed in various cancers, including some types of lymphoma. The frequency and prognostic significance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown. Materials and Methods: We assessed for survivin expression in 62 ALCL tumors (30 anaplastic lymphoma kinase [ALK]-positive and 32 ALK-negative) obtained before doxorubicin-based chemotherapy. Given that survivin is a target of the STAT3 signaling pathway and STAT3 is activated in ALCL, survivin expression was also correlated with STATS activation. Results: Survivin was expressed in 34 tumors (55%) and did not correlate with ALK. A significant association between survivin expression and STATS activation was observed (P = .007, Fisher's exact test). For the ALK-positive group, the 5-year failure-free survival (FFS) was 34% for patients with survivin-positive ALCL compared with 100% for patients with survivin-negative ALCL (P = .009, log-rank test). For the ALK-negative group, the 5-year FFS was 46% for patients with survivin-positive tumors compared with 89% for patients with survivin-negative tumors (P = .03, log-rank test). Overall survival was similarly worse for patients with survivin-positive tumors in both the ALK-positive and ALK-negative groups. Furthermore, multivariate analysis confirmed the independent prognostic value of survivin expression, along with age older than 60 years and Ann Arbor stage III or IV. Conclusion: Survivin is expressed in approximately half of ALCL tumors and independently predicts unfavorable clinical outcome. Modulation of survivin expression or function may provide a novel target for experimental therapy in patients with ALCL.
UR - http://www.scopus.com/inward/record.url?scp=2442675594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442675594&partnerID=8YFLogxK
U2 - 10.1200/JCO.2004.10.172
DO - 10.1200/JCO.2004.10.172
M3 - Article
C2 - 15117990
AN - SCOPUS:2442675594
SN - 0732-183X
VL - 22
SP - 1682
EP - 1688
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 9
ER -